Biopharmaceuticals were strong overall today, with two main themes. $Abbvie(ABBV.US) rose six points, having just announced the acquisition of Apogee for approximately $10.9 billion in cash at $135.11 per share, bolstering its next-generation immunology and inflammation pipeline. The market recognized this deal and reacted positively. $METIS TECHBIO-P(07666.HK) also rose six points, continuing the strong momentum since its IPO for this AI drug delivery Hong Kong-listed secondary new stock.
$Johnson & Johnson(JNJ.US) and $WUXI BIO(02269.HK) saw slight gains. The $SPDR S&P Biotech(XBI.US) rose three to four points, with overall sector sentiment leaning warm. Clinical-stage micro-cap stocks like $Eloxx Pharmaceuticals(ELOX.US) saw minor declines. Large pharmaceutical companies are using acquisitions to buy pipelines, and AI drug discovery is telling a new story. There was capital willing to flow into both of these lines in biopharma today.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
